Autophagy-related long non-coding RNA signature for ovarian cancer

Meng, Chan; Zhou, Jian; Liao, Yong-Sheng

doi:10.1177/0300060520970761

Cited by 51 publications

(48 citation statements)

References 30 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several autophagy related lncRNA signatures predicting the survival of patients have been proven in several cancers, including ovarian cancer, colorectal cancer, hepatocellular carcinoma, bladder urothelial carcinoma, breast cancer, colon adenocarcinoma, and glioma ( Luan et al, 2019 ; Meng et al, 2020 ; Sun et al, 2020 ; Wei et al, 2020 ; Wu et al, 2020 ; Zhou et al, 2020 ; Li et al, 2021 ). However, autophagy related lncRNA prognostic signature has not been investigated in AML.…”

Section: Discussionmentioning

confidence: 99%

A Prognostic Autophagy-Related Long Non-coding RNA (ARlncRNA) Signature in Acute Myeloid Leukemia (AML)

Zhao

Wang

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

BackgroundSome studies have proven that autophagy and lncRNA play important roles in AML. Several autophagy related lncRNA signatures have been shown to affect the survival of patients in some other cancers. However, the role of autophagy related lncRNA in AML has not been explored yet. Hence, this study aims to find an autophagy related lncRNA signature that can affect survival for AML patients.MethodA Pearson correlation analysis, a Kaplan–Meier survival curve, a univariate cox regression, and a multivariate cox regression were performed to establish an autophagy related lncRNA signature. A univariate cox regression, a multivariate cox regression, a Kaplan–Meier survival curve, and a ROC curve were applied to confirm if the signature is an independent prognosis for AML patients. The relationship between the signature and the clinical features was explored by using a T test. Gene Set Enrichment Analysis (GSEA) was used to investigate the potential tumor related pathways.ResultsA four-autophagy related lncRNA (MIR133A1HG, AL359715.1, MIRLET7BHG, and AL356752.1) signature was established. The high risk score based on signature was related to the short survival time of AML patients. The signature was an independent factor for the prognosis for AML patients (HR = 1.684, 95% CI = 1.324–2.142, P < 0.001). The signature was correlated with age, leukocyte numbers, and FAB (M3 or non-M3). The P53, IL6/JAK/STAT3, TNF-α, INF-γ, and IL2/STAT5 pathways might contribute to the differences between the risk groups based on signature in AML.ConclusionThe four autophagy related lncRNAs and their signature might be novel biomarkers for predicting the survival of AML patients. Some biological pathways might be the potential mechanisms of the signature for the survival of AML patients.

show abstract

Section: Discussionmentioning

confidence: 99%

A Prognostic Autophagy-Related Long Non-coding RNA (ARlncRNA) Signature in Acute Myeloid Leukemia (AML)

Zhao

Wang

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…The ROC curve suggested that the predictive potential of the risk-score model for OC patients was robust. In benchmark comparisons, the AUC (0.703) was comparable to or better than that of other published gene signatures (AUC: 0.604–0.813) ( Zhou et al, 2016 ; Yang et al, 2017 ; Meng et al, 2020 ; Zhao et al, 2021 ). Univariate and multivariate Cox regression analyses indicated that the risk score was an independent prognostic factor for OC.…”

Section: Discussionmentioning

confidence: 64%

A Potential Immune-Related Long Non-coding RNA Prognostic Signature for Ovarian Cancer

Pan

2021

Front. Genet.

View full text Add to dashboard Cite

Ovarian cancer (OC), the most lethal gynecologic malignancy, ranks fifth in cancer deaths among women, largely because of late diagnosis. Recent studies suggest that the expression levels of immune-related long non-coding RNAs (lncRNAs) play a significant role in the prognosis of OC; however, the potential of immune-related lncRNAs as prognostic factors in OC remains unexplored. In this study, we aimed to identify a potential immune-related lncRNA prognostic signature for OC patients. We used RNA sequencing and clinical data from The Cancer Genome Atlas and the Gene Expression Omnibus database to identify immune-related lncRNAs that could serve as useful biomarkers for OC diagnosis and prognosis. Univariate Cox regression analysis was used to identify the immune-related lncRNAs with prognostic value. Functional annotation of the data was performed through the GenCLiP310 website. Seven differentially expressed lncRNAs (AC007406.4, AC008750.1, AL022341.2, AL133351.1, FAM74A7, LINC02229, and HOXB-AS2) were found to be independent prognostic factors for OC patients. The Kaplan-Meier curve indicated that patients in the high-risk group had a poorer survival outcome than those in the low-risk group. The receiver operating characteristic curve revealed that the predictive potential of the immune-related lncRNA signature for OC was robust. The prognostic signature of the seven lncRNAs was successfully validated in the GSE9891, GSE26193 datasets and our clinical specimens. Multivariate analyses suggested that the signature of the seven lncRNAs was an independent prognostic factor for OC patients. Finally, we constructed a nomogram model and a competing endogenous RNA network related to the lncRNA prognostic signature. In conclusion, our study reveals novel immune-related lncRNAs that may serve as independent prognostic factors in OC.

show abstract

“…Similarly, USP30-AS1 is associated with prognosis in bladder cancer (54). This lncRNA was also associated with autophagy in ovarian cancer (55), and was related to immune response in cervical cancer (56) and glioblastoma (57). AL365361.1 was associated with good prognosis and immune response in head and neck squamous cell carcinoma (58) and with early recurrence in hepatocellular carcinoma (35).…”

Section: Discussionmentioning

confidence: 99%

Unraveling Immune-Related lncRNAs in Breast Cancer Molecular Subtypes

et al. 2021

View full text Add to dashboard Cite

Breast cancer (BRCA) is the most leading cause of cancer worldwide. It is a heterogeneous disease with at least five molecular subtypes including luminal A, luminal B, basal-like, HER2-enriched, and normal-like. These five molecular subtypes are usually stratified according to their mRNA profile patterns; however, ncRNAs are increasingly being used for this purpose. Among the ncRNAs class, the long non-coding RNAs (lncRNAs) are molecules with more than 200 nucleotides with versatile regulatory roles; and high tissue-specific expression profiles. The heterogeneity of BRCA can also be reflected regarding tumor microenvironment immune cells composition, which can directly impact a patient’s prognosis and therapy response. Using BRCA immunogenomics data from a previous study, we propose here a bioinformatics approach to include lncRNAs complexity in BRCA molecular and immune subtype. RNA-seq data from The Cancer Genome Atlas (TCGA) BRCA cohort was analyzed, and signal-to-noise ratio metrics were applied to create these subtype-specific signatures. Five immune-related signatures were generated with approximately ten specific lncRNAs, which were then functionally analyzed using GSEA enrichment and survival analysis. We highlighted here some lncRNAs in each subtype. LINC01871 is related to immune response activation and favorable overall survival in basal-like samples; EBLN3P is related to immune response suppression and progression in luminal B, MEG3, XXYLT1-AS2, and LINC02613 were related with immune response activation in luminal A, HER2-enriched and normal-like subtypes, respectively. In this way, we emphasize the need to know better the role of lncRNAs as regulators of immune response to provide new perspectives regarding diagnosis, prognosis and therapeutical targets in BRCA molecular subtypes.

show abstract

Autophagy-related long non-coding RNA signature for ovarian cancer

Cited by 51 publications

References 30 publications

A Prognostic Autophagy-Related Long Non-coding RNA (ARlncRNA) Signature in Acute Myeloid Leukemia (AML)

A Prognostic Autophagy-Related Long Non-coding RNA (ARlncRNA) Signature in Acute Myeloid Leukemia (AML)

A Potential Immune-Related Long Non-coding RNA Prognostic Signature for Ovarian Cancer

Unraveling Immune-Related lncRNAs in Breast Cancer Molecular Subtypes

Contact Info

Product

Resources

About